SUPPLY GUIDELINE MANAGEMENT

Supprelin LA (histrelin acetate)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication
Supprelin LA is indicated for the treatment of children with central precocious puberty (CPP).

B. Compendial Uses
1. Gender dysphoria (also known as gender non-conforming or transgender persons)
2. Preservation of ovarian function
3. Prevention of recurrent menstrual related attacks in acute porphyria

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

For central precocious puberty, submission of a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third-generation luteinizing hormone (LH) assay is required to initiate the prior authorization.

III. CRITERIA FOR INITIAL APPROVAL

A. Central precocious puberty (CPP)
1. Authorization of 12 months may be granted for treatment of CPP in a female member when all of the following criteria are met:
   a. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging, such as computed tomography (CT scan), magnetic resonance imaging (MRI), or ultrasound.
   b. The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third-generation LH assay.
   c. The assessment of bone age versus chronological age supports the diagnosis of CPP.
   d. The member was less than 8 years of age at the onset of secondary sexual characteristics.
2. Authorization of 12 months may be granted for treatment of CPP in a male member when all of the following criteria are met:
   a. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging, such as CT scan, MRI, or ultrasound.
   b. The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third-generation LH assay.
   c. The assessment of bone age versus chronological age supports the diagnosis of CPP.
   d. The member was less than 9 years of age at the onset of secondary sexual characteristics.
B. Gender dysphoria
1. Authorization of 12 months may be granted for pubertal hormonal suppression in an adolescent member when all of the following criteria are met:
   a. The member has a diagnosis of gender dysphoria.
   b. The member has reached Tanner stage 2 of puberty or greater.
2. Authorization of 12 months may be granted for gender transition when all of the following criteria are met:
   a. The member has a diagnosis of gender dysphoria.
   b. The member will receive Supprelin LA concomitantly with gender-affirming hormones.

C. Preservation of ovarian function
Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

D. Prevention of recurrent menstrual related attacks in acute porphyria
Authorization of 12 months may be granted for prevention of recurrent menstrual related attacks in members with acute porphyria when the requested medication is prescribed by or in consultation with a physician experienced in the management of porphyrias.

IV. CONTINUATION OF THERAPY

A. Central precocious puberty (CPP)
1. Authorization of up to 12 months may be granted for continuation of therapy for CPP in a female member if the member is currently less than 12 years of age and the member meets both of the following:
   a. The member is currently receiving the requested medication through a paid pharmacy or medical benefit.
   b. The member is not experiencing treatment failure such as clinical pubertal progression, lack of growth deceleration, and continued excessive bone age advancement.
2. Authorization of up to 12 months may be granted for continuation of therapy for CPP in a male member if the member is currently less than 13 years of age and the member meets both of the following:
   a. The member is currently receiving the requested medication through a paid pharmacy or medical benefit.
   b. The member is not experiencing treatment failure such as clinical pubertal progression, lack of growth deceleration, and continued excessive bone age advancement.

B. Gender Dysphoria
All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

C. All other indications
All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

V. REFERENCES